Monitor ISS's updated recommendation following this clarification. If dilution concerns are resolved, Proposal 4 is more likely to pass, preserving equity incentive capacity. The vote outcome will be known shortly after June 18, 2026.
ANIK drugs
ANIK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $14.63entry
- T+1 · 6mo ago −1.71%α −1.85% · $14.38
- T+5 · 5mo ago −1.03%α +1.72% · $14.48
- T+20 · 5mo ago 0.00%α +1.30% · $14.63
- T+60 · 3mo ago +46.27%α +45.04% · $21.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding under the Sixth Amended 2017 Omnibus Incentive Plan, excluding 476,221 shares underlying stock appreciation rights (SARs) that can be settled in cash. This clarification addresses ISS's unfavorable recommendation on Proposal 4 (approval of the Seventh Amended Plan) by potentially reducing the estimated dilution.
Key Financial Metrics
Key Facts
- ISS gave an unfavorable recommendation to the Seventh Amended Plan due to excessive dilution concerns.
- The supplement corrects the table on page 89 of the proxy statement: Stock Options Outstanding of 2,231,740 includes 476,221 shares underlying SARs that may be settled in cash or stock at the company's election.
- The Board unanimously recommends a vote FOR the Seventh Amended Plan.
- Annual Meeting of Stockholders is scheduled for June 18, 2026.
Financial Impact
No financial figures provided; correction may improve ISS recommendation and plan approval chances.
Risk Factors
- Shareholder rejection of the Seventh Amended Plan could limit the company's ability to grant equity awards.
- Continued ISS opposition could sway institutional votes against the plan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-023475 |
| Document: 0001140361-26-023475-index-headers.html | 0001140361-26-023475 |
| Document: 0001140361-26-023475-index.html | 0001140361-26-023475 |
| Document: 0001140361-26-023475.txt | 0001140361-26-023475 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Viewing Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers